BTKi, venetoclax, obinutuzumab: what is the ideal combination? | springermedizin.at
Skip to main content

Home

Zeitschriften

Zeitungen

Podcast

Gesundheitspolitik

Praxis

Leben

Jobs

Fachgebiete

Allgemeinmedizin
Anästhesiologie & Intensivmedizin
Augenheilkunde
Chirurgie
Dermatologie
Gynäkologie und Geburtshilfe
HNO
Innere Medizin
Kinder & Jugendheilkunde
Neurologie & Psychiatrie
Orthopädie & Unfallchirurgie
Pflege
Urologie
Zahnmedizin
Apotheke

Subfächer Innere Medizin

Diabetologie
Gastroenterologie
Infektiologie
Kardiologie
Onkologie und Hämatologie
Pneumologie
Rheumatologie

Fortbildungen

DFP-Literaturstudium-Artikel
DFP-Webcast Fortbildungen
DFP-Podcasts
Erweiterte Suche
Login
nach oben
memo - Magazine of European Medical Oncology

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: memo - Magazine of European Medical Oncology 1/2022

20.12.2021 | short review

BTKi, venetoclax, obinutuzumab: what is the ideal combination?

verfasst von: MD Daniel Heintel

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2022

Einloggen, um Zugang zu erhalten
share
TEILEN

Summary

Chronic lymphocytic leukemia (CLL) treatment strategies have improved and changed dramatically in the last few years. Currently, patients are mostly treated with so-called novel agents, including Bruton tyrosin kinase (BTK) inhibitors and BCL‑2 inhibitors. CLL is a chronic disease; therefore, a proportion of patients will require multiple lines of therapy. In this review, we present the current treatment options for patients with CLL and discuss potential optimal treatment combinations.
Vorheriger Artikel Bcl2 inhibitor venetoclax +/− Anti-CD20: what do deep remissions mean?
Nächster Artikel New actionable targets and investigational drugs in chronic lymphocytic leukemia
Literatur
1.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69:452–67. CrossRef
2.
Howlader N, Noone AM, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, et al. SEER cancer statistics review. Bethesda: National Cancer Institute; 2019. pp. 1975–2016.
3.
Eichhorst B, Robak T, Montserrat E, Ghia P, Niemann CU, Kater AP et al. Chronic lymphocytic leukaemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2021;32:23–33. CrossRef
4.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. IwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745–2760. CrossRef
5.
Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343:1910–6. CrossRef
6.
Zenz T, Eichhorst B, Busch R, Denzel T, Häbe S, Winkler D et al. TP53 mutation and survival in chronic lymphocytic leukemia. J Clin Oncol. 2010;28:4473–9. CrossRef
7.
Stilgenbauer S, Schnaiter A, Paschka P, Zenz T, Rossi M, Döhner K et al. Gene mutations and treatment outcome in chronic lymphocytic leukemia: results from the CLL8 trial. Blood. 2014;123:3247–54. CrossRef
8.
Tausch E, Schneider C, Robrecht S, Zhang C, Dolnik A, Bloehdorn J et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020;135:2402–12. CrossRef
9.
O’Brien S, Furman RR, Coutre S, Flinn IW, Burger JA, Blum K et al. Single-agent Ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5‑year experience. Blood. 2018;131:1910–9. CrossRef
10.
Shanafelt TD, Wang XV, Kay NE, et al. Ibrutinib–rituximab or chemoimmunotherapy for chronic lymphocytic leukemia. N Engl J Med 2019;381:432–443. CrossRef
11.
Woyach JA, Ruppert AS, Heerema NA, Zhao W, Booth AM, Ding W, et al. Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL. N Engl J Med. 2018;379(26):2517–2528. CrossRef
12.
Kater AP, Seymour JF, Hillmen P, Eichhorst B, Langerak AW, Owen C, et al. Fixed duration of venetoclax-rituximab in relapsed/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the Murano phase III study. J Clin Oncol. 2019;37(4):269–277. CrossRef
13.
Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et al. Fixed-duration venetoclax–obinutuzumab for previously untreated patients with chronic lymphocytic leukemia: follow-up of efficacy and safety results from the multicenter, open-label, randomized, phase III CLL14 trial. J Clin Oncol. 2020;21(9):1188–1200.
14.
Cheng S, Ma J, Guo A, Lu P, Leonard JP, Coleman M, et al. BTK inhibition targets in vivo CLL proliferation through its effects on B‑cell receptor signaling activity. Leukemia. 2014;28:649–57. CrossRef
15.
Herman SEM, Mustafa RZ, Gyamfi JA, Pittaluga S, Chang S, Chang B, et al. Ibrutinib inhibits BCR and NF-KB signaling and reduces tumor proliferation in tissue-resident cells of patients with CLL key points. Blood J Am Soc Hematol. 2014;123:3286–95.
16.
Moreno C, Greil R, Demirkan F, Tedeschi A, Anz B, Larratt L, et al. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (ILLUMINATE): a multicentre, Randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43–56. CrossRef
17.
Covey T, Gulranjani M, Cheung J, Bibikova E, Clevenger T, Krantz F, et al. Pharmacodynamic evaluation of acalabrutinib in relapsed/refractory and treatment-naive patients with chronic lymphocytic leukemia (CLL) in the phase 1/2 ACE-CL-001 study. Blood. 2020;26(12):2800–2809.
18.
Barf T, Covey T, Izumi R, van de Kar B, Gulrajani M, van Lith B, van Hoek M, de Zwart E, Mittag D, Demont D, Verkaik S, Krantz F, Pearson PG, Ulrich R, Kaptein A. Acalabrutinib (ACP-196): A Covalent Bruton Tyrosine Kinase Inhibitor with a Differentiated Selectivity and In Vivo Potency Profile. J Pharmacol Exp Ther. 2017;363(2):240–252. CrossRef
19.
Covey T, Barf T, Gulrajani M, Krantz F, van Lith B, Bibikova E, et al. Abstract 2596: ACP-196: a novel covalent Bruton’s tyrosine kinase (Btk) inhibitor with improved selectivity and in vivo target coverage inchronic lymphocytic leukemia (CLL) patients. Cancer Research 2015;75(15 Suppl):2596.
20.
Byrd JC, Harrington B, O’Brien S, Jones JA, Schuh A, Devereux S, et al. Acalabrutinib (ACP-196) in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):323–32. CrossRef
21.
Sharman JP, Egyed M, Jurczak W, Skarbnik A, Pagel JM, Flinn IW, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a Randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278–1291 CrossRef
22.
23.
Fischer K, Al-Sawaf O, Bahlo J, Fink AM, Tandon M, Dixon M, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225–2236. CrossRef
24.
Jain N, Keating M, Thompson P, Ferrajoli A, Burger J, Borthakur G et al. Ibrutinib and Venetoclax for first-line treatment of CLL. N Engl J Med. 2019;380:2095–103. CrossRef
25.
Hillmen P, Rawstron AC, Brock K, Muñoz-Vicente S, Yates FJ, Bishop R et al. Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study. J Clin Oncol. 2019;37:2722–9. CrossRef
Metadaten
Titel
BTKi, venetoclax, obinutuzumab: what is the ideal combination?
verfasst von
MD Daniel Heintel
Publikationsdatum
20.12.2021
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2022
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-021-00776-4

Weitere Artikel der Ausgabe 1/2022

memo - Magazine of European Medical Oncology 1/2022 Zur Ausgabe

short review

Checkpoint inhibitor pneumonitis: Short review of literature and case report

editorial

Innovative strategies in gastrointestinal cancer

short review

Hepatocellular carcinoma—neoadjuvant systemic and local treatment concepts to improve resectability rates and oncological outcome

short review

Treatment decision based on molecular profiling in metastatic colorectal cancer with a focus on RAS pathway mutations

case report

Immune-related hepatitis in a patient with hepatocellular carcinoma treated with nivolumab

short review

Practice-changing strategies in the treatment of esophageal cancer